Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €1.29 EUR
Change Today +0.003 / 0.23%
Volume 0.0
TEHN On Other Exchanges
As of 10:10 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

peregrine pharmaceuticals (TEHN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/9/15 - €1.51
52 Week Low
10/13/14 - €0.99
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

peregrine pharmaceuticals (TEHN) Related Businessweek News

No Related Businessweek News Found

peregrine pharmaceuticals (TEHN) Details

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States. Its lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer along with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also evaluating its lead molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of various solid tumor types. In addition, it provides contract manufacturing services ranging from cell line development to commercial current good manufacturing practice biomanufacturing to third-party clients. The company has various license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; and Merck KGaA. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.

180 Employees
Last Reported Date: 07/14/14
Founded in 1981

peregrine pharmaceuticals (TEHN) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $557.7K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $423.6K
Vice President, General Counsel and Corporate...
Total Annual Compensation: $393.8K
Vice President of Intellectual Property
Total Annual Compensation: $364.7K
Vice President of Clinical & Regulatory Affai...
Total Annual Compensation: $338.0K
Compensation as of Fiscal Year 2014.

peregrine pharmaceuticals (TEHN) Key Developments

Peregrine Pharmaceuticals, Inc. Announces Bavituximab Phase I Data Published in the Peer-Reviewed Journal Cancer Medicine in Advanced Metastatic Breast Cancer

Peregrine Pharmaceuticals, Inc. announced the peer-reviewed publication of clinical data from a Phase I investigator-sponsored trial evaluating the company's lead investigational immunotherapy bavituximab plus paclitaxel therapy in patients with HER2-negative metastatic breast cancer. The manuscript details the results of the Phase I trial showing that the combination produced an objective tumor response in 85% of patients, including 15% of these patients achieving a complete response, measured in accordance with Response Evaluation Criteria In Solid Tumors (RECIST) criteria. In the online released manuscript, researchers at the University of Arizona Medical Center led by Alison Stopeck, M.D. enrolled 14 patients with metastatic breast cancer (MBC) and while all were evaluable for toxicity, 13 were evaluable for response and progression free survival (PFS). These patients with HER2-negative MBC were treated with paclitaxel (80 mg/m2) weekly for three weeks of each four-week cycle and bavituximab (3 mg/kg) administered weekly beginning on day 15 after two weekly doses of paclitaxel. Results from 13 evaluable patients showed that 11 patients (85%) achieved an objective response, including two patients (15%) that achieved a complete response (CR), 9 patients with partial responses (PR) and 2 patients with progressive disease (PD). Median PFS for the combination of bavituximab with weekly paclitaxel was 7.3 months. In addition, the combination of bavituximab and paclitaxel was safe and well-tolerated with the majority of grade 1 or 2 adverse events being paclitaxel related. Approximately half of these patients were classified as "triple negative," a traditionally difficult-to-treat patient population. In addition, treatment with bavituximab reduced circulating PS-expressing microparticles (exosomes) which are immunosuppressive.

Peregrine Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended January 31, 2015

Peregrine Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended January 31, 2015. For the quarter, the company reported total revenues of $5,677,000 against $3,885,000 a year ago. Loss from operations was $13,022,000 against $9,743,000 a year ago. Net loss was $12,994,000 or $0.08 per basic and diluted share against $9,724,000 or $0.06 per basic and diluted share a year ago. For the nine months, the company reported total revenues of $17,473,000 against $15,927,000 a year ago. Loss from operations was $38,330,000 against $25,177,000 a year ago. Net loss was $38,223,000 or $0.23 per basic and diluted share against $25,114,000 or $0.16 per basic and diluted share a year ago.

Peregrine Pharmaceuticals, Inc. Declares Quarterly Cash Dividend on 10.50% Series E Convertible Preferred Stock, Payable on April 1, 2015

Peregrine Pharmaceuticals, Inc. announced that its Board of Directors has declared a quarterly cash dividend payment on the company's 10.50% Series E Convertible Preferred Stock (the Series E Preferred Stock). The quarterly dividend on the Series E Preferred Stock is payable on April 1, 2015 to holders of record at the close of business on March 20, 2015. The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from January 1, 2015 through March 31, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEHN:GR €1.29 EUR +0.003

TEHN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Argos Therapeutics Inc $8.56 USD -0.185
Dynavax Technologies Corp $23.31 USD -0.38
GenVec Inc $2.82 USD +0.01
Inovio Pharmaceuticals Inc $10.35 USD -0.25
Progenics Pharmaceuticals Inc $6.03 USD -0.375
View Industry Companies

Industry Analysis


Industry Average

Valuation TEHN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.6x
Price/Book 5.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PEREGRINE PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at